Who we are

celebrating 20 years Performance highlights

OUR SIX CAPITALS

  • Intellectual
    capital
  • Manufactured
    capital
  • Human
    capital
  • Social and
    relationship
    capital
  • Natural
    capital
  • Financial
    capital
  • Acquired the remaining rights to the intellectual property and manufacturing know-how of the anaesthetics portfolio from AstraZeneca
  • Serialisation projects on track to meet new regulatory requirements designed to combat counterfeit medicines reaching patients
  • 45 products launched in 20 countries
  • R2 145 million invested in capital replacement and expansion projects
  • Officially opened the high containment suite at our Port Elizabeth site
  • Significantly reduced safety, health and environmental risks at the Moleneind site
  • Implemented first year of new Human Resources strategy
  • 49,5% women in the workforce
  • R66 million invested in training our employees
  • Zero occupational fatalities
  • Eighth consecutive year of participating in the International Mandela Day Initiative, with Aspen assisting nearly 470 000 beneficiates through 456 projects in 39 countries over this period
  • Significantly improved score in the FTSE/JSE Responsible Investment Index to 4
  • Maintained our level 4 Broad-based Black Economic Empowerment (“BBBEE”) rating in South Africa
  • “B – Management“ performance rating for 2017 Carbon Disclosure Project (“CDP”) and Water CDP
  • 3,2% of waste generated sent to landfill, a reduction from 4,5% in 2017
  • Resource conservation and optimisation projects contributed to a 5,0% reduction in water used
  • Successful refinancing of the Group’s debt portfolio
  • Strong operating cash flow per share conversion rate of 105%
  • R5 886 million (31%) of wealth created reinvested in the Group

Group revenue by business segment
(%)

Group revenue by customer geography
(%)


COMMERCIAL PHARMACEUTICALS

REGIONAL
BRANDS
revenue
R14 336 million
5%
increase*

KEY BRANDS

  • Circadin
  • Foxair
  • Mybulen
  • Tribuss
  • Zyloric
ANAESTHETICS
revenue
R8 332 million
21%
increase*

KEY BRANDS

  • Diprivan
  • EMLA
  • Naropin
  • Ultiva
  • Xylocaine
THROMBOSIS
revenue
R6 430 million
12%
increase*

KEY BRANDS

  • Arixtra
  • Fraxiparine
  • Fraxodi
  • Mono-embolex
  • Orgaran
HIGH POTENCY
& CYTOTOXICS
revenue
R4 172 million
9%
decrease*

KEY BRANDS

  • Alkeran
  • Eltroxin
  • Imuran
  • Ovestin
  • Purinethol

* on a CER basis